on NanoViricides, Inc. (NASDAQ:NNVC)
Sustained Blood Concentration Profile of NV-387 Allows Infrequent Dosing
NanoViricides, Inc., a clinical-stage leader in antiviral nanomedicines, announces the desirable blood concentration profile of its broad-spectrum antiviral NV-387 in non-human primate models.
NV-387, administered intravenously, maintains a plateau of blood concentration with slow decline over 24 hours. This profile supports once-daily or less frequent dosing, attributed to the unique polymeric design minimizing renal loss.
The company has developed NV-387 for injection, infusion, and inhalation. The sustained blood profile makes it suitable for moderate to severe cases, with infusion for hospitalized patients.
NV-387 has shown potential against RSV, Influenza, and SARS-CoV-2, outperforming existing treatments like ribavirin and remdesivir in animal studies. This indicates a promising future for NV-387 in combating severe respiratory infections.
R. E.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NanoViricides, Inc. news